Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorRischin, Danny
dc.contributor.authorHarrington, Kevin
dc.contributor.authorGreil, Richard
dc.contributor.authorSoulières, Denis
dc.contributor.authorTahara, Makoto
dc.contributor.authorde Castro Junior, Gilberto
dc.contributor.authorBraña Garcia, Irene
dc.date.accessioned2022-08-18T09:13:28Z
dc.date.available2022-08-18T09:13:28Z
dc.date.issued2022-05
dc.identifier.citationRischin D, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro Jr G, et al. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. Oral Oncol. 2022 May;128:105815.
dc.identifier.issn1879-0593
dc.identifier.urihttps://hdl.handle.net/11351/8013
dc.descriptionImmunoteràpia; Pembrolizumab; Qualitat de vida
dc.description.sponsorshipFunding for this research was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesOral Oncology;128
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectCap - Càncer - Tractament
dc.subjectColl - Càncer - Tractament
dc.subjectQuimioteràpia combinada
dc.subject.meshSquamous Cell Carcinoma of Head and Neck
dc.subject.mesh/drug therapy
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.titlePembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.oraloncology.2022.105815
dc.subject.decscarcinoma de células escamosas de cabeza y cuello
dc.subject.decs/farmacoterapia
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada
dc.relation.publishversionhttps://doi.org/10.1016/j.oraloncology.2022.105815
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Rischin D] Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia. [Harrington KJ] Radiotherapy and Imaging, The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust, National Institute for Health Research Biomedical Research Centre, London, United Kingdom. [Greil R] Hematology and Medical Oncology, Paracelsus Medical University, Salzburg Cancer Research Institute, and Cancer Cluster Salzburg, Salzburg, Austria. [Soulières D] Haematology/Oncology, Centre Hospitalier de l’Université de Montréal, Montreal, Canada. [Tahara M] Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan. [de Castro G Jr] Medical Oncology, Instituto do Câncer do Estado de São Paulo, São Paulo, Brazil. [Braña I] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid35381576
dc.identifier.wos000792907400009
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple